PTY vs. IBB, HTGC, DNP, ADX, USA, NUV, GSBD, RVT, TY, and GAB
Should you be buying PIMCO Corporate & Income Opportunity Fund stock or one of its competitors? The main competitors of PIMCO Corporate & Income Opportunity Fund include iShares Biotechnology ETF (IBB), Hercules Capital (HTGC), DNP Select Income Fund (DNP), Adams Diversified Equity Fund (ADX), Liberty All-Star Equity Fund (USA), Nuveen Municipal Value Fund (NUV), Goldman Sachs BDC (GSBD), Royce Value Trust (RVT), Tri-Continental (TY), and The Gabelli Equity Trust (GAB). These companies are all part of the "investment offices, not elsewhere classified" industry.
PIMCO Corporate & Income Opportunity Fund (NYSE:PTY) and iShares Biotechnology ETF (NASDAQ:IBB) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
PIMCO Corporate & Income Opportunity Fund has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, iShares Biotechnology ETF has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Given iShares Biotechnology ETF's higher probable upside, analysts plainly believe iShares Biotechnology ETF is more favorable than PIMCO Corporate & Income Opportunity Fund.
PIMCO Corporate & Income Opportunity Fund pays an annual dividend of $1.43 per share and has a dividend yield of 9.9%. iShares Biotechnology ETF pays an annual dividend of $0.41 per share and has a dividend yield of 0.3%.
In the previous week, iShares Biotechnology ETF had 2 more articles in the media than PIMCO Corporate & Income Opportunity Fund. MarketBeat recorded 3 mentions for iShares Biotechnology ETF and 1 mentions for PIMCO Corporate & Income Opportunity Fund. iShares Biotechnology ETF's average media sentiment score of 0.47 beat PIMCO Corporate & Income Opportunity Fund's score of -1.00 indicating that iShares Biotechnology ETF is being referred to more favorably in the news media.
10.3% of PIMCO Corporate & Income Opportunity Fund shares are held by institutional investors. Comparatively, 62.5% of iShares Biotechnology ETF shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
iShares Biotechnology ETF received 35 more outperform votes than PIMCO Corporate & Income Opportunity Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 64.92% of users gave PIMCO Corporate & Income Opportunity Fund an outperform vote.
Summary
iShares Biotechnology ETF beats PIMCO Corporate & Income Opportunity Fund on 7 of the 9 factors compared between the two stocks.
Get PIMCO Corporate & Income Opportunity Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
PIMCO Corporate & Income Opportunity Fund Competitors List
Related Companies and Tools